Luke Evnin

Dr. Luke Evnin is Managing Director of MPM Capital, an investment firm he co-founded in 1997.

MPM remains dedicated to founding and investing in life sciences companies that seek to translate scientific innovations into clinical outcomes and currently is investing across several funds and over $2.5 billion of committed capital. Over the past seven years, as a component of his MPM activities, Luke has been a co-founder and served as chairman of the board for seven of MPM portfolio companies including Amphivena Therapeutics, Blade Therapeutics, Harpoon Therapeutics, Maverick Therapeutics, Potenza Therapeutics, Tizona Therapeutics and Werewolf Therapeutics. He has contributed as a co-inventor in Werewolf and in several other of these companies as well as MPM portfolio company Oncorus. And, from October 2017 to June 2019, Dr. Evnin served as the interim Chief Executive Officer of Werewolf Therapeutics, Inc., where he continues to serves as chairman of its board of directors. In addition, he currently serves, on behalf of MPM Capital, as a director for eight other private companies. He was the lead investor and served on the boards of several of MPM’s most successful investments including CoStim, Idun Pharmaceuticals, and Pacira.

Dr. Evnin has also served on the board of directors of many other public and private companies over his 28-year venture capital career, including past service as a director of Syndax Pharmaceuticals, Inc., EnteroMedics Inc. (now known as ReShape Lifesciences Inc.), Epix Medical, Inc., Intercell AG, Metabasis Therapeutics, Inc. (acquired by Ligand Pharmaceuticals, Inc.), Oscient Pharmaceuticals Corp., Pacira Pharmaceuticals Inc., Restore Medical, Inc. (acquired by Medtronic, Inc.), Sonic Innovations, Inc. and Signal Pharmaceuticals, Inc. (acquired by Celgene Corporation).

Dr. Evnin also serves as chairman of the board of directors of the Scleroderma Research Foundation, a not-for-profit entity where he has contributed for over 20 years. In recognition of MPM’s novel work, Luke was a recipient of the 2017 Global Oncology Visionary Award.

Prior to co-founding MPM, he honed his skills as a venture capitalist at Accel Partners. Dr. Evnin holds a Ph.D. in Biochemistry (1990) from the University of California at San Francisco (UCSF).